Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
Status:
Completed
Trial end date:
2021-10-15
Target enrollment:
Participant gender:
Summary
This study is a Phase 1, single-center, open-label study to investigate the absorption,
metabolism, and excretion of BTZ-043 after a single oral administration of 500 mg BTZ-043
containing 3.7 MBq of [14C]BTZ-043 in 4 healthy adult male subjects
Phase:
Phase 1
Details
Lead Sponsor:
Michael Hoelscher
Collaborator:
Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institut